RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas

Genome Research

Volumn 24, Issue 11, 2014, Pages 1765-1773

  Bao, Zhao Shi ^a,b,c   Chen, Hui Min ^d   Yang, Ming Yu ^d   Zhang, Chuan Bao ^a,b,c   Yu, Kai ^d   Ye, Wan Lu ^d   Hu, Bo Qiang ^d   Yan, Wei ^e   Zhang, Wei ^b,c   Akers, Johnny ^f   Ramakrishnan, Valya ^f   Li, Jie ^f   Carter, Bob ^f   Liu, Yan Wei ^a,b,c   Hu, Hui Min ^a   Wang, Zheng ^a,b,c   Li, Ming Yang ^a,b,c   Yao, Kun ^c,g   Qiu, Xiao Guang ^b,c   Kang, Chun Sheng ^c,h   You, Yong Ping ^c,e   Fan, Xiao Long ⁱ   Song, Wei Sonya ^a,j   Li, Rui Qiang ^d   Su, Xiao Dong ^d   Chen, Clark C ^f   Jiang, Tao ^a,b,c,j   more..

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Chinese Glioma Cooperative Group (CGCG)   (China)

^d PEKING UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h TIANJIN MEDICAL UNIVERSITY   (China)

ⁱ BEIJING NORMAL UNIVERSITY   (China)

^j BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYBRID PROTEIN; ISOCITRATE DEHYDROGENASE 1; PROTEIN; PTPRZ PROTEIN; RNF213 PROTEIN; SCATTER FACTOR RECEPTOR; SLC26A11 PROTEIN; TACC3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ALKYLATING AGENT; DACARBAZINE; MET PROTEIN, HUMAN; ONCOPROTEIN; PTPRZ1 PROTEIN, HUMAN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; TEMOZOLOMIDE;

ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTRON; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; BRAIN TUMOR; CHEMORADIOTHERAPY; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; GLIOMA; HEK293 CELL LINE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SEQUENCE ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DACARBAZINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLIOMA; HEK293 CELLS; HUMANS; INTRONS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, RNA; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84927166354     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.165126.113     Document Type: Article

References (47)

1. Appin CL, Brat DJ. 2014. Molecular genetics of gliomas. Cancer J 20: 66-72.
2. Audic SP, Claverie JM. 1997. The significance of digital gene expression profiles. Genome Res 7: 986-995.
3. Bartek J, Bartkova J, Lukas J. 2007. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26: 7773-7779.
4. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870.
5. Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, Laursen H, Kalita O, Kolar Z, Poulsen HS, Broholm H, et al. 2010. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 29: 5095-5102.
6. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, et al. 2010. Integrative analysis of the melanoma transcriptome. Genome Res 20: 413-427.
7. Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, Lamszus K. 2003. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52: 1391-1399.
8. The Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
9. Ciriello G, Cerami E, Sander C, Schultz N. 2012. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 22: 398-406.
10. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. 1984. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311: 29-33.
11. Deshpande A, Sicinski P, Hinds PW. 2005. Cyclins and cdks in development and cancer: a perspective. Oncogene 24: 2909-2915.
12. Diamantopoulou Z, Kitsou P, Menashi S, Courty J, Katsoris P. 2012. Loss of receptor protein tyrosine phosphatase b/z (RPTPb/z) promotes prostate cancer metastasis. J Biol Chem 287: 40339-40349.
13. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. 2009. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15: 2207-2214.
14. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. 1997. The CDKN2A (p16) gene and human cancer. Mol Med 3: 5-20.
15. Kangaspeska S, Hultsch S, Edgren H, Nicorici D, Murumagi A, Kallioniemi O. 2012. Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple isoforms. PLoS ONE 7: e48745.
16. Kim D, Salzberg SL. 2011. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 12: R72.
17. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760.
18. Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cazares H, Eberhart CG, et al. 2011. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci 108: 9951-9956.
19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
20. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, Griffith M, Heravi Moussavi A, Senz J, Melnyk N, et al. 2011. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 7: e1001138.
21. Mohebiany AN, Nikolaienko RM, Bouyain S, Harroch S. 2013. Receptor-type tyrosine phosphatase ligands: looking for the needle in the haystack. FEBS J 280: 388-400.
22. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. 2008. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621-628.
23. Muller S, Kunkel P, Lamszus K, Ulbricht U, Lorente GA, Nelson AM, von Schack D, Chin DJ, Lohr SC, Westphal M, et al. 2003. A role for receptor tyrosine phosphatasez inglioma cell migration. Oncogene 22: 6661-6668.
24. Nambiar M, Kari V, Raghavan SC. 2008. Chromosomal translocations in cancer. Biochim Biophys Acta 1786: 139-152.
25. Negrini S, Gorgoulis VG, Halazonetis TD. 2010. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220-228.
26. Ng K, Kim R, Kesari S, Carter B, Chen CC. 2012. Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol 107: 1-12.
27. Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Furnari F, Hoadley KA, et al. 2010. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS ONE 5: e10767.
28. Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H. 2013. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126: 931-937.
29. Ohgaki H, Kleihues P. 2009. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100: 2235-2241.
30. Organ SL, Tsao MS. 2011. An overview of the c-MET signaling pathway. Ther Adv Med Oncol 3: S7-S19.
31. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, et al. 2013. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 123: 855-865.
32. Ren R. 2005. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172-183.
33. Sajan SA, Hawkins RD. 2012. Methods for identifying higher-order chromatin structure. Annu Rev Genomics Hum Genet 13: 59-82.
34. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. 2010. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46: 1773-1780.
35. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Yu SB, et al. 2012. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22: 2109-2119.
36. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, et al. 2012. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337: 1231-1235.
37. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290.
38. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
39. Torti D, Trusolino L. 2011. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 3: 623-636.
40. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
41. Wade M, Li YC, Wahl GM. 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13: 83-96.
42. Wang Y, Jiang T. 2013. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett 331: 139-146.
43. Weinstein IB. 2002. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
44. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N Engl J Med 359: 492-507.
45. Wickramasinghe D, Kong-Beltran M. 2005. Met activation and receptor dimerization in cancer: a role for the Sema domain. Cell Cycle 4: 683-685.
46. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. 2009. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
47. Zhou JB, Zhang T, Wang BF, Gao HZ, Xu X. 2013. Identification of a novel gene fusion RNF213-SLC26A11 in chronic myeloid leukemia by RNA-Seq. Mol Med Rep 7: 591-597.